VivoSim Labs Inc
Research VivoSim Labs Inc (VIVS) on Bullrun: market cap USD 839.41K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVIVS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 839.41K
- Financial periodQ1 2026
- RevenueUSD 40.00K
- Net income-USD 5.76M
- Free cash flow-USD 2.24M
- Gross margin100.0%
Valuation Snapshot
latest market cap is USD 839.41K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 144.00K | -USD 2.49M | -USD 9.47M | 96.5% | -1.7 | USD 11.31M | USD 577.00K | USD 10.49M |
| FY2024 | USD 109.00K | -USD 14.67M | -USD 14.70M | n/a | -19.25 | USD 2.90M | USD 1.06M | USD 3.60M |
| FY2023 | USD 370.00K | -USD 17.26M | -USD 12.80M | n/a | -1.98 | USD 15.30M | n/a | USD 15.33M |
| FY2022 | USD 1.50M | -USD 11.45M | -USD 8.86M | n/a | -1.32 | USD 28.68M | n/a | USD 30.21M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 839.41K | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.71M | 3.9 | n/a | n/a |
| 2024 | 2024-12-31 | USD 7.88M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 10.88M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 12.29M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 31.60M | n/a | n/a | n/a |
About VivoSim Labs Inc
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is VivoSim Labs Inc's market cap?
VivoSim Labs Inc's market capitalization is USD 839.41K.
What does VivoSim Labs Inc do?
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.